NDLI: Targeting DNA damage in SCLC

Please wait, while we are loading the content...

Targeting DNA damage in SCLC

Content Provider	Scilit
Author	Foy, Victoria Schenk, Maximilian W. Baker, Katie Gomes, Fabio Lallo, Alice Frese, Kristopher K. Forster, Martin Dive, Caroline Blackhall, Fiona
Copyright Year	2017
Description	Journal: Lung Cancer SCLC accounts for 15% of lung cancer worldwide. Characterised by early dissemination and rapid development of chemo-resistant disease, less than 5% of patients survive 5 years. Despite 3 decades of clinical trials there has been no change to the standard platinum and etoposide regimen for first line treatment developed in the 1970's. The exceptionally high number of genomic aberrations observed in SCLC combined with the characteristic rapid cellular proliferation results in accumulation of DNA damage and genomic instability. To flourish in this precarious genomic context, SCLC cells are reliant on functional DNA damage repair pathways and cell cycle checkpoints. Current cytotoxic drugs and radiotherapy treatments for SCLC have long been known to act by induction of DNA damage and the response of cancer cells to such damage determines treatment efficacy. Recent years have witnessed improved understanding of strategies to exploit DNA damage and repair mechanisms in order to increase treatment efficacy. This review will summarise the rationale to target DNA damage response in SCLC, the progress made in evaluating novel DDR inhibitors and highlight various ongoing challenges for their clinical development in this disease.
Related Links	https://core.ac.uk/download/pdf/143422653.pdf
Ending Page	22
Page Count	11
Starting Page	12
ISSN	01695002
e-ISSN	18728332
DOI	10.1016/j.lungcan.2017.10.006
Journal	Lung Cancer
Volume Number	114
Language	English
Publisher	Elsevier BV
Publisher Date	2017-12-01
Access Restriction	Open
Subject Keyword	Journal: Lung Cancer Checkpoint Inhibitors Dna Repair Pathways Lung Cancer Parp Inhibitors Small Cell Lung Cancer
Content Type	Text
Resource Type	Article
Subject	Pulmonary and Respiratory Medicine Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

DNA repair in lung cancer: potential not yet reached.

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study

Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.

Exploiting DNA damage repair defects for effective targeting of acute myeloid leukaemia by PARP inhibitors

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer.

Advances and challenges in immunotherapy of small cell lung cancer.

PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches.

Small Cell Lung Cancer: A New Era is Beginning?

Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer

Targeting DNA damage in SCLC

Similar Documents

DNA repair in lung cancer: potential not yet reached.

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study

Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.

Exploiting DNA damage repair defects for effective targeting of acute myeloid leukaemia by PARP inhibitors

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer.

Advances and challenges in immunotherapy of small cell lung cancer.

PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches.

Small Cell Lung Cancer: A New Era is Beginning?

Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer

Targeting DNA damage in SCLC